Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fayette

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2019
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trialO Trédan, Q Wang, D Pissaloux, et al.
ESMO Open|January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerP Heudel, S Chabaud, D Perol, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2019
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trialO Trédan, Q Wang, D Pissaloux, et al.
ESMO Open|January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerP Heudel, S Chabaud, D Perol, et al.
Pageof 3